<DOC>
	<DOC>NCT00729651</DOC>
	<brief_summary>To demonstrate the efficacy/safety of Fosamax Plus D</brief_summary>
	<brief_title>Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Patient agrees to apply sunscreen and limit sunlightexposure to 1 hour per day during the study Patient has been diagnosed with osteoporosis Patient has been postmenopausal for more than 6 months Patient has no contraindication to taking oral bisphosphonates Patient is eligible for dual energy xray absorptiometry in spine or hip Patients with esophageal dysfunction Patients who can not sit or stand at least 30 minutes Patients who had a malignant disease or active systemic disease 5 years prior to participating in this trial Patients with diseases of bone or mineral metabolism besides osteoporosis or receiving therapies which affect bone metabolism or calcium metabolism Patients with history of major gastrointestinal disease (peptic ulcer, malabsorption, esophageal disease, gastritis, gastroduodenitis, etc.) within the last 6 months</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>